Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2003 Mar 10;88(5):684-8.

A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin.

Author information

  • 1Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.


Using data from the population-based Prescription Database of North Jutland County and the Danish Cancer Registry, we compared cancer incidence among 29 470 individuals prescribed low-dose aspirin at maximum doses of 150 mg with expected incidence based on county-specific cancer rates, during a 9-year study period. We observed 2381 cancer cases compared with 2187 expected, yielding a standardised incidence ratio (SIR) of 1.09 (95% confidence interval (CI), 1.05-1.13). No apparent risk reductions were found for cancers of the colon (SIR, 0.9; 95% CI, 0.7-1.1) or rectum (SIR, 1.0; 95% CI, 0.8-1.2), or for other site-specific cancers. Increased SIRs were observed for kidney cancer (SIR, 1.4; 95% CI, 1.1-1.7) and brain cancer (SIR, 1.7; 95% CI, 1.3-2.2), although the excess in the latter was confined to the first year of follow-up. Stratification by number of prescriptions and duration of follow-up revealed no apparent trends. The SIR for colorectal cancer was close to unity (SIR, 0.9; 95% CI, 0.6-1.2) among persons with 10 or more prescriptions who were followed for at least 5 years. Our results do not support a major protective effect of low-dose aspirin on the development of colorectal or other cancers. The observed excesses of kidney and brain cancers are not likely to be causally related to the use of low-dose aspirin.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk